Bilirubin-Induced Transcriptomic Imprinting in Neonatal Hyperbilirubinemia

Biology (Basel). 2023 Jun 8;12(6):834. doi: 10.3390/biology12060834.

Abstract

Recent findings indicated aberrant epigenetic control of the central nervous system (CNS) development in hyperbilirubinemic Gunn rats as an additional cause of cerebellar hypoplasia, the landmark of bilirubin neurotoxicity in rodents. Because the symptoms in severely hyperbilirubinemic human neonates suggest other regions as privileged targets of bilirubin neurotoxicity, we expanded the study of the potential impact of bilirubin on the control of postnatal brain development to regions correlating with human symptoms. Histology, transcriptomic, gene correlation, and behavioral studies were performed. The histology revealed widespread perturbation 9 days after birth, restoring in adulthood. At the genetic level, regional differences were noticed. Bilirubin affected synaptogenesis, repair, differentiation, energy, extracellular matrix development, etc., with transient alterations in the hippocampus (memory, learning, and cognition) and inferior colliculi (auditory functions) but permanent changes in the parietal cortex. Behavioral tests confirmed the presence of a permanent motor disability. The data correlate well both with the clinic description of neonatal bilirubin-induced neurotoxicity, as well as with the neurologic syndromes reported in adults that suffered neonatal hyperbilirubinemia. The results pave the way for better deciphering the neurotoxic features of bilirubin and evaluating deeply the efficacy of new therapeutic approaches against the acute and long-lasting sequels of bilirubin neurotoxicity.

Keywords: brain development; corplot; gene clustering; histone acetylation; kernicterus; motor disabilities; neurologic syndrome; opisthotonus; schizophrenia.

Grants and funding

This research was funded in part by an internal grant of Fondazione Italiana Fegato (S.G., D.P., C.T. and in part J.P.L.), and in part by the Department of Science and Technology through the Philippine Council for Health Research and Development (DOST-PCHRD) (J.P.L).